|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||2.2800 - 2.2800|
|52 Week Range||1.8500 - 2.6000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MALAKOFF, France, November 22, 2021--Regulatory News: THERACLION (Paris:ALTHE) (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for noninvasive echotherapy providing consistent, data driven and evidence-based patient care, announces today the completion of the first varicose veins echotherapy treatment in China. The first milestone of our study, which will open the way to Asian markets.
MALAKOFF, France, September 23, 2021--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing a scalable robotic platform for none invasive treatment by echotherapy including varicose veins, announces today its annual results for the first 6 months of the year ended 30 June 2021 with a complete recovery from COVID period and ambitious development plans in Europe and in the US.
MALAKOFF, France, September 21, 2021--Regulatory News: THERACLION (ISIN: FR0010120402; Mnemo: ALTHE, PEA-PME eligible) (Paris:ALTHE), an innovative company specialized in echotherapy treatment (using High Intensity Focused Ultrasound or HIFU), announces FDA (Food & Drug Administration) approval for the first trial with SONOVEIN in the United States (US). After this clinical trial, a full pivotal study will be conducted for FDA review for market authorisation.